This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
cll
CLL
Most common adult leukemia; clonal CD5+/CD19+/CD23+ B-cell malignancy; del(17p)/TP53 mutation is highest-risk. Ibrutinib and venetoclax transformed CLL; obinutuzumab+venetoclax is first-line for unfit patients; pirtobrutinib is active in covalent BTK-inhibitor-resistant CLL.
Entry Metadata
| Field | Value |
|---|---|
| ID | cll |
| Name | CLL |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236. · PubMed 31166681
- Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432-443. · PubMed 31365801